Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 787 results for "Tecfidera"

Human medicines European public assessment report (EPAR): Te...

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ... European Medicines Agency, 1 week ago

4 images for Tecfidera

Motley Fool, 1 month ago, 4 weeks ago
Pharma Letter, 1 month ago
ABC News 4 Charleston, 1 month ago

Can Biogen Idec Take Wing With Tecfidera?

Summary Biogen reported strong Q2 results and raised guidance. Tecfidera for multiple sclerosis was the key growth driver in the quarter. Using reasonable EPS growth estimates, Biogen looks attractive for longer-term investors. Biogen Idec ...
 Seeking Alpha3 weeks ago Biogen revenue trounces forecast as MS drug sales surge  CNBC1 month ago Storming Tecfidera sales drive 46 profit rise at Biogen  Big News Network4 weeks ago UPDATE 4-Biogen revenue trounces forecast as MS drug sales surge  Reuters1 month ago
Motley Fool

dimethyl fumarate (Tecfidera)

Pharmacy Author: Omudhome Ogbru, PharmD Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University ...
 MedicineNet.com2 days ago Denmark's Forward Pharma to launch IP attack on Biogen Idec's MS superstar Tecfidera  FiercePharma1 week ago IQWiG finds no added benefit for Biogen Idec's Tecfidera08-08-2014  Pharma Letter1 week ago Denmarks Forward Pharma to launch IP attack on Biogen Idecs MS superstar Tecfidera  Big News Network1 week ago

TECFIDERA, a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed in Alberta

MISSISSAUGA, ON, Aug. 7, 2014 /CNW/ -Biogen Idec Canada announces today that Alberta Health will now reimburse TECFIDERA (dimethyl fumarate) through the Alberta Drug Benefit List
 Canada NewsWire2 weeks ago ViewPoints: Biogen Idec banks on demand to offset lower pricing for Tecfidera in Europe  FirstWord Pharma2 weeks ago TECFIDERA(TM), a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed in Alberta  Individual.com2 weeks ago Biogen Idec Canada Release: British Columbia To Reimburse TECFIDERA???, A First-Line Oral Treatment For Multiple Sclerosis  BioSpace1 month ago

Multiple sclerosis treatment landscape has undergone dramatic changes during 2013

The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen's Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market share from older therapies. However, patent ...
 TransWorldNews3 weeks ago Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules  Pettinga Financial Advisors1 month ago

Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues

It was a busy week in the biotech sector with quite a few major companies reporting second quarter earnings. Outperformers included companies like Biogen ( BIIB ) and Gilead ( GILD ) both reported impressive numbers that sailed past expectations. ...
 Yahoo! Finance3 weeks ago Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress - Analyst Blog  Zacks.com2 weeks ago Alexion, 3 Other Top Biotechs Reporting Earnings  Investor's Business Daily1 month ago

Biogen Trounces Q2 Estimates As Tecfidera Outperforms

Big-cap biotech Biogen Idec (NASDAQ: BIIB ) soundly beat analysts' Q2 expectations and substantially raised its guidance early Wednesday, sending shares up more than 11% in midday trading in the stock market today to near 338, a four-month high. ...
 Investor's Business Daily1 month ago Video: Biogen Trounces Q2 Estimates On Tecfidera  Investor's Business Daily1 month ago

Biogen's Q2 Earnings Surpass Expectations, Tecfidera Shines

Biogen Idec (BIIB) reported second quarter 2014 earnings per share of $3.48 (including the impact of stock-based compensation expense), way above the Zacks Consensus Estimate of $2.80 and the year-ago earnings of $2.29 per share. While oral ...
 Yahoo! Finance1 month ago Biogen Idec Stock Spikes Following Second Quarter Earnings Beat  TheStreet.com1 month ago

Biogen Beats Quarterly Analyst Estimates with New Drug Sales

Biogen Idec Inc. (BIIB) , maker of multiple sclerosis drugs Avonex, Tysabri and Tecfidera, beat analyst estimates with better than expected sales of Tecfidera and new hemophilia drug Alprolix. The company raised its 2014 forecast. Net income for ...
 Bloomberg1 month ago Pop some corks, Tecfidera sales folks: Your $700M for Q2 trounced estimates  FiercePharma1 month ago

Could This 1 Lawsuit Destroy Biogen Idec Stock?

Source: Biogen IDEC. Biogen 's ( NASDAQ: BIIB ) Tecfidera launched a year ago, and it has already become a blockbuster likely to notch more than $2 billion in sales this year. Much of Tecfidera's success is coming at the expense of recently ...
 Motley Fool1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less